Erodium is a pioneering breakthrough in poultry farming. It fights Campylobacter and cutting-edge probiotics to ensure safer food and sustainable agriculture.
Antibiotic resistance (AMR) is one of the biggest threats to health worldwide and has a major impact on both human and animal populations. One of the most widespread foodborne pathogens, Campylobacter affects 10% of the global population each year, and poultry is the leading airline. Current solutions, including biosecurity measurements and antibiotics, are no longer sufficient, especially as regulatory standards become more stringent. Biotechnology company Elogium is tackling this challenge with Elosafe+, an innovative probiotic feed additive designed to reduce campylobacter colonization in poultry.
Probiotic breakthrough
Elosafe+ is based on a naturally occurring unique strain of subspecies PS-216, originally isolated from Slovenian riverbank soils. Extensive research and vitro testing have demonstrated the ability to significantly reduce Campylobacter, Salmonella and Listeria in poultry without the use of antibiotics. Unlike existing probiotics, Elosafe+ has a strong anti-effect against antibiotic-resistant Campylobacter strains.
In vivo challenge studies conducted using broiler chickens, there was a significant reduction in Campylobacter levels in the cecal, with 1.4 logs reduced when administered continuously via drinking water. Furthermore, studies have shown that feed conversion rates (FCR) improvements increased by up to 2.6%, reducing feed consumption, resulting in increased sustainability.
The need for innovation
With increasing restrictions on antibiotics in animal agriculture, producers were looking for effective alternatives. Traditional biosecurity measurements alone are insufficient for large-scale foodborne pathogen approaches, and Campylobacter is the biggest cause of foodborne diseases around the world, making effective and natural interventions a reality. Demand is important. Elogium’s cutting-edge probiotics are poised to fill this gap, offering scientifically validated, antibiotic-free solutions that benefit both poultry farmers and consumers.
Extend your Elosafe+ application beyond poultry
While Elosafe+ is primarily intended to reduce Campylobacter in poultry, Elogium is leveraging its proprietary Bacillus subtilis PS-216 strain to develop probiotics for additional livestock applications. Research is currently underway to extend the benefits of this strain to pigs, cattle, and aquaculture, with early trials showing promising effects on intestinal health and disease resistance of multiple species.
Industry awareness and support
Elogium is widely recognized for its innovative approach. The company was created with a commercial reactor venture building program and has since been significantly recognized in major European incubators. The company was awarded the Best Team at the EIT Food Seed Incubator (2022) and later approved for the Biotope Incubator in Ghent, Belgium, further solidifying its location in the European Biotechnology Ecosystem. Additionally, Elogium recently received the prestigious Womentecheu grant, a highly competitive program with acceptance rates of less than 5%, highlighting the company’s innovation and impact in the biotech sector.
The science behind erosium
Elogium’s research is supported by leading microbiology and food safety experts. The team includes:
Karlis Udris – CEO, overseeing business strategy and commercialization. Dr. Katarina Simnovich – Chief Executive of Campylobacter, expert on foodborne pathogens. Dr. Polonca Stefanič – Bacillus subtilis interaction expert and head of Bacillus. The professor is Manditch Murek – a scientific advisor and well-known microbiologist. Claude Dhont – Business Advisor, extensive experience in animal health and diagnostics.
Their research has been recognized in multiple publications in peer-reviewed journals, enhancing the scientific reliability of subtilis PS-216 as an innovative probiotic.
Regulation pathways and challenges
To bring new probiotic solutions to the market, you will need to navigate strict regulatory approvals. Elogium has developed a comprehensive regulatory roadmap that will ensure that Elosafe+ is approved as a Zootechnical Feed additive. This process involves extensive vitro and in vivo studies to demonstrate efficacy and safety, in line with the standards of the European Food Safety Agency (EFSA). By the end of 2025, Elogium expects to complete all necessary research and submit regulatory cases with full approval by the end of 2027.
One of the key hurdles to obtaining regulatory approval is the demonstration of consistent effectiveness under real-world farm conditions. To address this, Elogium has collaborated with industry partners to conduct large field trials to provide robust data to regulators while ensuring that Elosafe+ provides measurable benefits to poultry farmers. It is offered.
Commercial Strategy and Market Expanding
Elogium’s business model is centered around a joint development partnership with established animal health companies. This approach allows Elogium to focus on research and regulatory approval, leveraging its partner manufacturing, branding and distribution expertise. The company has already secured letters of intent (LOI) with animal health companies around the world, setting the stage for long-term collaboration and market penetration.
From a market size perspective, Elogium initially targeted the 120 million euro European market with the goal of gaining 10% market share (12 million euros) over the next five years. Furthermore, financial incentives to reduce Campylobacter contamination in poultry could significantly expand market opportunities and potentially increase the company’s target market share three to five times.
The road ahead
Elogium has already raised 325,000 euros stock and convertor memos, and is part of the major startup incubators, including EIT food nurseries and Biotope by Vib. Looking ahead, the company aims to complete a joint development agreement, complete EFSA submissions, and launch Elosafe+ in the EU market by 2027.
The company is also sought new strategic partnerships and investment opportunities to accelerate growth, expand manufacturing capabilities and expand into additional markets. With its strong scientific foundations and regulatory momentum, Erodium is positioned to redefine probiotic solutions in animal agriculture.
As the poultry industry moves towards antibiotic-free solutions, Elogium’s groundbreaking technology brings the opportunity to change the game to increase food safety, improve animal health and promote sustainable farming practices Provided.
This article will also be featured in the 21st edition of Quarterly Publication.
Source link
